Table 5.
Expression of CD34, smooth muscle actin and glutamine synthetase in patients with chemotherapy-induced SOS
| Case | Histologic Grade | Trichrome | Immunohistochemistry Grade | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| No. | Agea | SI | NRH | VO | SOS-I | CD34 | SMA | GS | CSI score | Chemotherapy (cycle #) | |
| 1 | 70–74 | 3 | 1 | 0 | 4 | 1 | 3 | 3 | 0 | 6 | capecitabine and oxaliplatin (2) |
| 2 | 65–69 | 3 | 1 | 0 | 4 | 1 | 3 | 3 | 0 | 6 | FOLFOX (4) |
| 3 | 65–69 | 3 | 1 | 0 | 4 | 0 | 3 | 3 | 0 | 6 | capecitabin, oxaliplatin (2) and cetuximab |
| 4 | 55–59 | 3 | 1 | 0 | 4 | 0 | 3 | 1 | 3 | 7 | FOLFOX (*) and bevacizumab |
| 5 | 65–69 | 3 | 1 | 0 | 4 | 1 | 3 | 2 | 3 | 8 | FOLFOX (*) |
| 6 | 60–64 | 3 | 1 | 0 | 4 | 1 | 3 | 3 | 3 | 9 | FOLFOX (6) |
| 7 | 70–74 | 3 | 1 | 0 | 4 | 0 | 2 | 3 | 0 | 5 | FOLFOX and bevacizumab (6) |
| 8 | 50–54 | 2 | 1 | 0 | 3 | 1 | 0 | 0 | 0 | 0 | FOLFOX (6) |
| 9 | 70–74 | 2 | 1 | 0 | 3 | 1 | 2 | 0 | 0 | 2 | FOLFOX (*) |
| 10 | 65–69 | 2 | 1 | 0 | 3 | 0 | 2 | 3 | 0 | 5 | FOLFOX (*) and bevacizumab |
| 11 | 65–69 | 3 | 0 | 0 | 3 | 1 | 3 | 3 | 2 | 8 | FOLFOX (4) |
| 12 | 55–59 | 3 | 0 | 0 | 3 | 1 | 3 | 3 | 1 | 7 | FOLFOX (3) and bevacizumab |
| 13 | 75–79 | 2 | 1 | 0 | 3 | 0 | 3 | 0 | 0 | 3 | FOLFOX (*) |
| 14 | 70–74 | 0 | 1 | 2 | 3 | 1 | 0 | 3 | 3 | 6 | FOLFOX (12) |
| 15 | 30–34 | 1 | 1 | 0 | 2 | 0 | 2 | 3 | 0 | 5 | FOLFOX (8), converted to FOLFIRI and bevacizumab |
| 16 | 50–54 | 2 | 0 | 0 | 2 | 1 | 2 | 3 | 0 | 5 | FOLFOX (6) and cetuximab |
| 17 | 50–54 | 2 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | FOLFOX (8), converted to FOLFIRI, bevacizumab and cetuximab |
| 18 | 55–59 | 2 | 0 | 0 | 2 | 0 | 0 | 3 | 0 | 3 | FOLFOX (4) and bevacizumab |
| 19 | 45–49 | 2 | 0 | 0 | 2 | 1 | 1 | 3 | 3 | 7 | FOLFOX (5) and cetuximab converted to FOLFIRI |
| 20 | 55–59 | 1 | 1 | 0 | 2 | 0 | 1 | 0 | 0 | 1 | FOLFOX (6) |
| 21 | 55–59 | 2 | 0 | 0 | 2 | 1 | 2 | 3 | 0 | 5 | FOLFOX (*), converted to FOLFIRI, avastin and cetuximab |
| 22 | 50–54 | 1 | 1 | 0 | 2 | 1 | 2 | 0 | 0 | 2 | FOLFIRI and cetuximab |
| 23 | 55–59 | 1 | 0 | 0 | 1 | 1 | 0 | 2 | 0 | 2 | none |
| 24 | 60–64 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 1 | none |
| 25 | 50–54 | 0 | 1 | 0 | 1 | 1 | 2 | 0 | 0 | 2 | none |
| 26 | 70–74 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | none |
| 27 | 60–64 | 1 | 0 | 0 | 1 | 1 | 0 | 3 | 0 | 3 | none |
| 28 | 55–59 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | none |
| 29 | 85–89 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | none |
| 30 | 75–79 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | none |
aAges were replaced by age ranges to maintain partient confidentiality
SOS sinusoidal obstruction syndrome, SI sinusoidal injury, NRH nodular regenerative hyperplasia, VO venous obstruction, SOS-I SOS index, SMA smooth muscle actin, GS glutamine synthetase, CSI score chemotherapy-induced sinusoidal injury score, OX oxaliplatin, *unknown cycle